Invex Therapeutics Ltd. (AU:IXC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Invex Therapeutics Ltd has announced the retirement of Dr. Megan Baldwin as a Non-executive director, effective 30 June 2024. Baldwin, who joined the biopharmaceutical company in February 2021, played a pivotal role in advancing their leading drug, Exenatide, from Phase II to Phase III clinical trials for treating neurological conditions related to increased intracranial pressure. The company expressed gratitude for her significant contributions and wished her well in future endeavors.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.